AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Expanding eligibility criteria for lung cancer screening to include 20-year smoking history without requiring a certain ...

While presenting the data at this year's American Society of Clinical Oncology (ASCO) annual meeting, Peter Voorhees, MD, of ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated ...

CSL's R&D chief says the company's new hereditary angioedema treatment is one of only a few drugs to be built from scratch in ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...